The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review

被引:23
作者
Braat M.N.G.J.A. [1 ]
Samim M. [2 ]
van den Bosch M.A.A.J. [1 ]
Lam M.G.E.H. [1 ]
机构
[1] Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht
[2] Department of Surgery, University Medical Center Utrecht, Utrecht
关键词
Bridge to transplant; Downstaging; Future liver remnant; Radioembolization;
D O I
10.1007/s40336-016-0172-0
中图分类号
学科分类号
摘要
Radioembolization (RE) is an emerging treatment strategy for patients with primary hepatic malignancies and metastatic liver disease. Though RE is primarily performed in the palliative setting, a shift toward the curative setting is seen. Currently, hepatic resection and in selected cases liver transplantation are the only curative options for patients with a hepatic malignancy. Unfortunately, at diagnosis most patients are not eligible for liver surgery due to the imbalance between the necessary liver resection and the remaining liver remnant. However, in borderline resectable cases, tumor volume reduction and/or increasing the future liver remnant can lead to a resectable situation. The combination of selective tumor treatment, the induction of hypertrophy of untreated liver segments, and its favourable toxicity profile make RE an appealing strategy for downstaging. The present review discusses the possibilities for RE in the preoperative setting as a downstaging tool or as a bridge to liver transplantation. © 2016, The Author(s).
引用
收藏
页码:283 / 295
页数:12
相关论文
共 108 条
  • [1] Altekruse S.F., Henley S.J., Cucinelli J.E., McGlynn K.A., Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States, Am J Gastroenterol, 109, 4, pp. 542-553, (2014)
  • [2] Bray F.J.A., Grey N., Et al., Global cancer transitions according to the human development index (2008–2030): a population-based study, Lancet Oncol, 13, 8, pp. 790-801, (2012)
  • [3] Mosadeghi S., Liu B., Bhuket T., Wong R.J., Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the U.S.: an updated analysis of the 2000–2011 surveillance, epidemiology, and end results registry, Hepatol Res, (2015)
  • [4] Abdalla E.K., Adam R., Bilchik A.J., Jaeck D., Vauthey J.N., Mahvi D., Improving resectability of hepatic colorectal metastases: expert consensus statement, Ann Surg Oncol, 13, 10, pp. 1271-1280, (2006)
  • [5] Adam R.D.V., Pascal G., Et al., Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival, Ann Surg, 240, 4, pp. 644-658, (2004)
  • [6] Inarrairaegui M.P.F., Bilbao J.I., Et al., Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma, Eur J Surg Oncol, 38, 7, pp. 594-601, (2012)
  • [7] Kopetz S., Chang G.J., Overman M.J., Eng C., Sargent D.J., Larson D.W., Et al., Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, J Clin Oncol, 27, 22, pp. 3677-3683, (2009)
  • [8] Jones R.P., Hamann S., Malik H.Z., Fenwick S.W., Poston G.J., Folprecht G., Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer, Eur J Cancer, 50, 9, pp. 1590-1601, (2014)
  • [9] Andreou A., Aloia T.A., Brouquet A., Dickson P.V., Zimmitti G., Maru D.M., Et al., Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy, Ann Surg, 257, 6, pp. 1079-1088, (2013)
  • [10] Rees M., Tekkis P.P., Welsh F.K., O'Rourke T., John T.G., Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients, Ann Surg, 247, 1, pp. 125-135, (2008)